Nutra Pharma Announcing Launch of Luxury Feet
Nutra Pharma is announcing the launch of Luxury Feet; an over-the-counter pain reliever for women who experience pain or discomfort due to high heels and stilettos.
June 21, 2017 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that they are expanding their product line with the introduction of Luxury Feet; an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos.
"Women who chronically wear high heels are prone to a variety of foot problems, including pain, bunions, hammer toe and Plantar fasciitis," commented Rik J Deitsch, CEO of Nutra Pharma. “We know that women spend upwards of $600 for a pair of shoes and certainly would like to wear them without fear of pain," he continued. "Luxury Feet is a new product that can be used safely every day. We know that this product can prevent or treat the pain and inflammation caused by your favorite footwear," he concluded.
According to a survey by The American Podiatric Medical Association: 72% of women wear high-heeled shoes, 58% of women purchased new high-heeled shoes in the last year, 59% report toe pain as a result of wearing uncomfortable shoes while 54% report pain in the ball of the foot. When asked why women wear high heels: 82% “for fashion or style”; 73% “to complete my professional attire”; 54% “to look sexier and more attractive”; 48% “to enhance my legs”; and 39% “to appear taller”
"I appreciate the opportunity to introduce our newest product, Luxury Feet," commented Nina Goldstein, Marketing Manager of Nutra Pharma. “To all the ladies out there who feel the pain after a day in heels, relief is just around the corner,” she continued. “We have already begun the pre-marketing process and have seen a lot of excitement in the marketplace. Luxury Feet will be available shortly for purchase on our website followed by a retail rollout later this year. Beauty no longer needs to be painful,” she concluded.
Luxury Feet is an over-the-counter (OTC) homeopathic pain reliever that relies on natural cobra venom’s ability to alleviate pain and inflammation. The product is designed specifically to treat foot and ankle pain in women that can be caused by wearing high heels, pumps or stiletto shoes. Luxury Feet is available as a topical roll-on gel that can be used every day for the prevention and treatment of foot and ankle pain.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com or http://www.nyloxin.com http://www.petpainaway.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The launch of Luxury Feet should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.